- Male and female participants who are overtly healthy as determined by medical
evaluation including a detailed medical history, full physical examination, which
includes blood pressure (BP) and pulse rate measurement, clinical laboratory tests,
and 12-lead ECG.
- Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lb).
- Evidence or history of clinically significant hematological, renal, endocrine,
pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or
allergic disease (including drug allergies, but excluding untreated, asymptomatic,
seasonal allergies at the time of dosing).
- Evidence or history of clinically significant dermatological condition (eg, contact
dermatitis or psoriasis) or visible rash present during physical examination.
- Participant with a history of known hypersensitivity to itraconazole or its excipients
or to other azole antifungals.
- History of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C;
positive testing for HIV, hepatitis B core antibody (HBcAb), hepatitis B surface
antigen (HBsAg), or hepatitis C antibody (HCVAb). Hepatitis B vaccination is allowed.
- History of tuberculosis or active or latent or inadequately treated infection,
positive QuantiFERON®- tuberculosis (TB) Gold or equivalent test.
- Have a history of any lymphoproliferative disorder (such as Epstein Barr Virus [EBV]
related lymphoproliferative disorder, as reported in some participants on other
immunosuppressive drugs), history of lymphoma, leukemia, myeloproliferative disorders,
multiple myeloma, or signs and symptoms suggestive of current lymphatic disease.
- Have or have had clinically significant infections within the past 3 months prior to
the first dose of investigational product (eg, those requiring hospitalization or
parenteral antibiotics, or as judged by the Investigator), evidence of any infection
within the past 7 days prior to the first dose of investigational product, herpes
simplex within 12 weeks or history of disseminated herpes simplex infection,
symptomatic herpes zoster or recurrent (>1 episode) or disseminated herpes zoster.
- Have undergone significant trauma or major surgery within 4 weeks of Screening.
- Have been vaccinated with live or attenuated live vaccine within the 6 weeks prior to
the first dose of investigational product, or expects to be vaccinated with these
vaccines during study treatment, or within the 6 weeks following the last dose of
investigational product.Recombinant subunit vaccines (eg, Shingrix®) are permitted and
it is preferable that the last dose is administered at least 4 weeks prior to Day 1.
- Use of prescription or nonprescription drugs and dietary and herbal supplements within
7 days or 5 half-lives (whichever is longer) prior to the first dose of
investigational product.
- Female participants taking hormone replacement therapy within 28 days prior to the
first dose of study treatment.
- A positive urine drug test.
- Screening supine BP ?140 mm Hg (systolic) or ?90 mm Hg (diastolic), following at least
5 minutes of supine rest. If BP is ?140 mm Hg (systolic) or ?90 mm Hg (diastolic), the
BP should be repeated 2 more times and the average of the 3 BP values should be used
to determine the participant's eligibility.
- Baseline 12-lead ECG that demonstrates clinically relevant abnormalities that may
affect participant safety or interpretation of study results (eg, baseline QTc
interval >450 msec, complete left bundle branch block [LBBB], signs of an acute or
indeterminate-age myocardial infarction, ST-T interval changes suggestive of
myocardial ischemia, second- or third-degree atrioventricular [AV] block, or serious
bradyarrhythmias or tachyarrhythmias).
- Participants with abnormalities in clinical laboratory tests at screening, as assessed
by the study-specific laboratory
- History of alcohol abuse or binge drinking and/or any other illicit drug use or
dependence within 6 months of Screening.
- Use of tobacco/nicotine containing products in excess of 5 cigarettes/day.
- Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more
within 60 days prior to dosing.
- History of sensitivity to heparin or heparin-induced thrombocytopenia
- Female participants of childbearing potential who are unwilling or unable to use a
highly effective method of contraception for the duration of the study and for at
least 60 days after the last dose of itraconazole.
- Female nursing participants will be excluded.